RET and adrenal gland pheochromocytoma: Sunitinib is an oral tyrosine kinase inhibitor targeting vascular endothelial factor receptor 1 and 2, PDGF-B receptor, RET and other tyrosine kinases including FGFR that is overexpressed in PCC/PGL.18 We conducted a multicentre open label single arm phase 2 study of sunitinib in patients with locally advanced unresectable or metastatic PCC/PGL who had demonstrated progression or who had disease-related symptoms.